New drug trial targets rare bone cancer with few treatment options

NCT ID NCT04950075

Ongoing Disease control Sponsor: Inhibrx Biosciences, Inc Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called INBRX-109 for people with advanced chondrosarcoma, a rare bone cancer that cannot be removed by surgery or has spread. The main goal is to see if the drug can slow or stop the cancer's growth better than a placebo. Researchers will measure how long patients live without their cancer getting worse and monitor their quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AP-HM - Hôpital de la Timone

Marseille, 13005, France
AP-HP Hopital Cochin

Paris, France
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

Palermo, 90127, Italy
Centre Antoine-Lacassagne

Nice, France
Centre Eugene Marquis

Rennes, France
Centre Leon Berard

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Chris O'Brien Lifehouse

Camperdown, 2050, Australia
Churchill Hospital

Oxford, OX3 7LJ, United Kingdom
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Columbia University

New York, New York, 10032, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02114, United States
Duke University

Durham, North Carolina, 27710, United States
Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, 20133, Italy
Groningen UMC

Groningen, 9713 GZ, Netherlands
Gustave Roussy

Villejuif, 94805, France
Helios Klinikum Berlin-Buch

Berlin, 13125, Germany
Hospital Clinico San Carlos

Madrid, 28040, Spain
Hospital Clinico Universitario de Santiago

Santiago de Compostela, Spain
Hospital Fundación Jiménez Díaz

Madrid, 28040, Spain
Hospital Universitari i Politecnic La Fe

Valencia, 46026, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario Virgen del Rocio

Seville, Spain
Hospital de la Santa Creu i Sant Pau Barcelona

Barcelona, 08041, Spain
ICM - Institut Regional du Cancer de Montpellier

Montpellier, France
IRCCS Istituto Ortopedico Rizzoli di Bologna

Bologna, 40136, Italy
Institut Bergonie

Bordeaux, Cedex, 33076, France
Johns Hopkins

Baltimore, Maryland, 21287, United States
La Fondazione e l'Istituto di Candiolo

Candiolo, 10060, Italy
Leiden University Medical Center

Leiden, 2333 ZA, Netherlands
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic - Jacksonville

Jacksonville, Florida, 32224, United States
Mayo Clinic Cancer Center

Phoenix, Arizona, 85054, United States
Mayo Clinic Rochester

Rochester, Minnesota, 99505, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10021, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Nebraska Methodist Hospital

Omaha, Nebraska, 68114, United States
Norris Cotton Cancer Center

Lebanon, New Hampshire, 03766, United States
Northwestern University - Robert H. Lurie Comprehensive Cancer Center

Chicago, Illinois, 60611, United States
Nuovo Ospedale di Prato

Prato, 59100, Italy
Oregon Health & Science University (OHSU) Knight Cancer Institute

Portland, Oregon, 97201, United States
Policlinico Universitario Campus Biomedico

Roma, 00128, Italy
Precision NextGen Oncology & Research Center

Beverly Hills, California, 90212, United States
Princess Alexandra Hospital

Woolloongabba, Australia
Royal Adelaide Hospital

Adelaide, 5000, Australia
Royal Marsden NHS Foundation Trust

London, SW3 6JJ, United Kingdom
Rush Cancer Center

Chicago, Illinois, 60612, United States
Saint Vincent's University Hospital part of Irish Sarcoma Group

Dublin, D04 T6F4, Ireland
Sarcoma Oncology Center

Santa Monica, California, 90403, United States
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States
Universitaetsklinikum Heidelberg

Heidelberg, Germany
Universitaetsklinikum Tuebingen

Tübingen, Germany
University College London Hospital (UCL)

London, NW1 2PG, United Kingdom
University of California, San Francisco (UCSF)

San Francisco, California, 94110, United States
University of Colorado

Denver, Colorado, 80220, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Oklahoma - Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
University of Texas Southwestern

Dallas, Texas, 75390, United States
University of Washington

Seattle, Washington, 98109, United States
Universitätsmedizin Mannheim

Mannheim, 68167, Germany
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States
Washington University School of Medicine - St. Louis

St Louis, Missouri, 63110, United States
Yale Cancer Center

New Haven, Connecticut, 06519, United States

Conditions

Explore the condition pages connected to this study.

CONVENTIONAL CHONDROSARCOMA